Experimental combo shot for pancreatic cancer stalls after just 2 patients
NCT ID NCT04387071
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This very early trial tested two immune-stimulating drugs injected directly into tumors for people with stage IV pancreatic cancer. The goal was to see if the combination could shrink tumors or slow their growth. However, the study was stopped early after enrolling only 2 participants, so we have very little information about how well it worked or what side effects it caused.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CMP-001 (a virus-like particle that activates the immune system) and INCAGN01949 (an antibody that stimulates immune cells)
What this could lead to
If it had worked, this approach could have pointed toward a new way to treat advanced pancreatic cancer by using the body's own immune system to attack tumors.
What could go wrong
This trial was very early (phase 1/2) and was terminated after only 2 participants, so we have almost no data on whether it works or is safe. The combination may cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hoag Memorial Hospital
Newport Beach, California, 92663, United States
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
Lucile Packard Children's Hospital Stanford University
Palo Alto, California, 94304, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States